* Arcadia Biosciences Inc RKDA.OQ RKDA.O is expected
to show a
rise in quarterly revenue when it reports results on November
10.
* The Davis California-based company is expected to report
a
12.3% increase in revenue to $2.669 million from $2.38 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Arcadia Biosciences
Inc
is for a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Arcadia
Biosciences Inc is $3.25, above its last closing price
of $0.34.
This summary was machine generated November 9 at 03:05 GMT. All
figures in US dollars unless otherwise stated